Halozyme Therapeutics News and Activities

Presence

Halozyme Therapeutics develops and commercializes drug delivery technologies and biotechnology therapies. Its products and services support pharmaceutical partners, healthcare providers, and patients in oncology, immunology, and other treatment areas.

Halozyme Therapeutics products and services overview:

Drug delivery technology
Biologic therapies
Injection solutions
Licensing services
Pharmaceutical partnerships

Revenue: ~$1 billion

Employees: 450

Headquarters: San Diego, United States (USA)

Halozyme Therapeutics is one of the...

Halozyme Therapeutics is a company listed under the stock ticker HALO (US).

Acquisition, funding and merger involving Halozyme Therapeutics.

Halozyme Therapeutics has announced the acquisition of Elektrofi (posted on October 2 2025).

Executives

View the org chart displaying its 33 main executives

Most searched biographies at Halozyme Therapeutics

Popular executive movements at Halozyme Therapeutics

Cortney Caudill, Senior Vice President and Chief Operations Officer, has left the company (posted on July 3 2026).
David Ramsay who was Interim Chief Financial Officer, becomes President, Drug Delivery (posted on July 2 2026).
Darren Snellgrove will join the company as Chief Financial Officer on Jun. 8, 2026 (posted on April 30 2026).

Click here to view some more movements at Halozyme Therapeutics

Create your alert
to follow the executive moves at Halozyme Therapeutics.